Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Pioneering Treatment | Immunovant's novel anti-FcRn therapy shows promise for autoimmune diseases, particularly Graves' disease, with potential for best-in-class efficacy |
Market Potential | Explore the substantial opportunity in Graves' disease, with an estimated 20,000 high-need patients diagnosed annually in the US |
Analyst Optimism | Price targets range from $36 to $58, suggesting significant upside potential despite recent stock decline. Average target stands at $57 |
Strategic Expansion | Delve into Immunovant's ambitious plan to target 10 indications by 2026, diversifying risk and expanding market potential |
Metrics to compare | IMVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMVTPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.4x | −4.0x | −0.5x | |
PEG Ratio | 0.14 | −0.01 | 0.00 | |
Price/Book | 3.7x | 2.5x | 2.6x | |
Price / LTM Sales | - | 151.9x | 3.3x | |
Upside (Analyst Target) | 182.9% | 196.4% | 43.5% | |
Fair Value Upside | Unlock | 6.5% | 6.8% | Unlock |